https://de.marketscreener.com/kurs/aktie/ARROWHEAD-PHARMACEUTICALS-26864651/news/Arrowhead-Pharmaceuticals-beginnt-Phase-1-2a-Studie-mit-ARO-DM1-zur-Behandlung-der-Myotonen-Dystroph-46129512/?utm_source=telegram&utm_medium=social&utm_campaign=share